Companies: 10,795·Total market cap: $144.5T
TG Therapeutics, Inc.

TG Therapeutics, Inc.

TGTXNASDAQHealthcare● Active
$40.95
+$0.79(+1.97%)
Market Cap$6.3B
P/E Ratio—
52W High$44.65
52W Low$25.28
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

TG Therapeutics, Inc. (TGTX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · TGTX · as of Jun 9, 2026

Key Statistics

EPS (TTM)$3.18tgtx eps ttm · tgtx earnings per shareEarnings history
PE Ratio (TTM)12.9×tgtx pe ratio ttm · tgtx price to earningsPE Ratio deep dive
Revenue (TTM)$700.3Mtgtx revenue ttm · tgtx annual revenueFull revenue history
Dividend YieldNo Dividenddoes tgtx pay dividends · tgtx dividend yieldDividend history
Shares Outstanding144.3Mtgtx shares outstanding · tgtx floatShares outstanding history
Next EarningsAug 3, 2026Est.tgtx earnings date · tgtx next earningsEarnings history

Explore TG Therapeutics, Inc. Data

tgtx stock data · financials
Market Cap$6.3Btgtx market cap · tgtx valuation
Analyst Forecast$55 · Buy
DividendsNo Dividenddoes tg therapeutics, inc. pay dividends · tgtx dividend yield
Revenue$616.3M+87.32%tg therapeutics, inc. annual revenue · tgtx revenue
EarningsEPS $3.10+1837.50%tgtx earnings · tgtx eps
PE Ratio12.9×tgtx pe ratio · tgtx price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$616.3M▲ +87.32% YoY
202320242025
tg therapeutics, inc. revenue · tgtx revenue 2025
FY 2025Net Income$447.2M▲ +1812.41% YoY
202320242025
tg therapeutics, inc. net income · tgtx profit 2025
FY 2025EPS$3.10▲ +1837.50% YoY
202320242025
tgtx eps · tg therapeutics, inc. earnings per share 2025
TTM:Revenue: $700.3MNet Income: $461.9MEPS: $3.18View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy13 analystsis tgtx a buy · tgtx analyst rating
Strong Buy
0
Buy
11
Hold
1
Sell
1
Strong Sell
0
12-Month Price Target
$39.00Low
$40.95Current
$54.50Avg Target33.09% upside
$70.00High
tgtx price target · tgtx 12 month forecast

Total: 13 · Buy rate: 84.6%

The TGTX analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $54.50, representing +33.09% upside from the current price of $40.95.

Stock Performance

Full History
1D+1.97%
1W+6.17%
1M-4.46%
3M+39.90%
YTD+37.37%
1Y+2.79%
5Y+10.20%

About TG Therapeutics, Inc.

CEOMichael S. Weiss
IPO DateMay 3, 2010
Employees352
CountryUS
Websitetgtherapeutics.com

TG Therapeutics, Inc. Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advanc…

BiotechnologyHealthcareNASDAQUS

what is tg therapeutics, inc. · tgtx stock overview · tg therapeutics, inc. company profile · who is tg therapeutics, inc. ceo · tgtx NASDAQ · tg therapeutics, inc. headquarters · tg therapeutics, inc. business segments

About Stock Overview & Key Data

TG Therapeutics, Inc. (TGTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 3, 2010. As of the latest trading session, TGTX stock price is $40.95, with a market capitalization of $6.3B. The stock has returned +2.79% over the past 12 months and +37.37% year-to-date.

According to 13 Wall Street analysts, the consensus rating for TG Therapeutics, Inc. stock is Buy, with an average 12-month price target of $54.50. In fiscal year 2025, TG Therapeutics, Inc. reported revenue of $616.3M and net income of $447.2M. For detailed data — including TG Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, TG Therapeutics, Inc. (TGTX) stock price is $40.95. The stock is traded on NASDAQ under the ticker symbol TGTX. The 52-week range is $25.28 – $44.65.

TGTX stock priceTGTX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice